
PP63. AIDIT AND IMPACT: STRENGTHENING RESEARCH TIES IN EASTERN EUROPE Luleci G1, Doherty R2, Lubinski J3, MANGUOGLU E1, Christie M2, Bancroft E2, Mitra A2, Morgan S2, Zieba K3, Eeles R2
1. Department of Medical Biology and Genetics, Faculty of Medicine, Akdeniz University, Antalya, Turkey; 2. The Institute of Cancer Research, London, United Kingdom; 3. International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
e-mail: luleci@akdeniz.edu.tr
*Corresponding Author: page: 76
|
Abstract
AIDIT (Advancing International Co-operation and Developing Infrastructure for Targeted Screening of Prostate Cancer in Men with Genetic Predisposition) is a project funded by the Sixth Framework Programme of the European Community which aims to facilitate co-operation between European countries in the field of cancer research. AIDIT will focus on linking clinical and research teams in associated candidate countries and new member states of the European Union with the IMPACT consortium, an international team investigating screening and diagnosis for men with a genetic risk of prostate cancer (carriers of BRCA1 or BRCA2 gene mutations). Cancer research is most successful when centralised and well co-ordinated, avoiding the duplication and fragmentation associated with smaller, isolated studies. AIDIT provides the opportunity for teams who might be new to this field of research to become integrated into an existing study. Communication between new and existing collaborators will allow the sharing of knowledge and formulation of strategies to overcome local barriers and challenges. AIDIT will establish and present a website to facilitate communication between project collaborators, and arrange a funded conference to bring together international research teams, clinicians and policy makers. The project will also aim to raise awareness of familial prostate cancer among health professionals and the public within Associate Candidate Countries and New Member States of the EU. Enquiries about attending the conference are welcome. This poster reflects only the authors' views. The European Community is not liable for any use that may be made of the information contained therein.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|